Amneal Pharmaceuticals In... (AMRX)

Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price apprecia...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-C...

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results.

Evaluate the expected performance of Amneal (AMRX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...

J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfoli...